Summary Recent studies suggest that aberrations of c-erbB-2 may be involved in astrocytic brain tumours. We screened immunohistochemically c-erbB-2 protein (p185) expression in 94 astrocytic grade 1 -4 neoplasms of the brain. The amplification of the c-erbB-2 oncogene was investigated in protein overexpression cases by dual colour fluorescence in situ hybridisation (FISH). p185 overexpression was correlated with p53 and epidermal growth factor receptor (EGFR) expression, as well as with clinicopathological features. Only two anaplastic (grade 3) astrocytomas and one gliobastoma (grade 4) showed overexpression of p185 protein by immunohistochemistry (monoclonal MAb antibody TA250), whereas none of the grade 1 -2 astrocytomas was positive. Interestingly, the expression of p185 was confined solely to the cytoplasm of neoplastic astrocytic cells and not to the cell membranes as found in malignancies with amplification of the c-erbB-2 oncogene. Two of the three overexpression cases were also positive by EGFR. No amplification of the c-erbB-2 gene was observed by FISH in the three tumours with immunohistochemical p185 overexpression or seven weakly positive/negative tumours. In conclusion, our results suggest that p185 overexpression is infrequent in astrocytomas, that it is of no important diagnostic or prognostic value and that c-erbB-2 oncogene amplification is not seen in the few cases in which there is overexpression.
Increased expression of c-erbB-2 protein (pl85) is associated with malignant cell transformation and poor prognosis in several tumours (Slamon et al., 1987 (Slamon et al., , 1989 Yokota et al., 1988) . p185 is a transmembrane glycoprotein of 185 kDa with tyrosine kinase activity that shares homology with the epidermal growth factor receptor (EGFR) (Schechter et al., 1985; Akiyama et al., 1986) and is assumed to be involved in the regulation of cell growth and differentiation. p185 is a receptor for a still poorly characterised growth factor ligand (Lupu et al., 1992) . The c-erbB-2 gene is located on chromosome 17q21 and it is often amplified in human breast, ovarian and gastric cancer (Slamon et al., 1987 (Slamon et al., , 1989 Yokota et al., 1988) . The degree of amplification is related to p185 protein expression, high cell proliferation rate and poor prognosis (Slamon et al., 1987 (Slamon et al., , 1989 .
Although amplification of the EGFR gene has been found in astrocytic neoplasms, particularly in glioblastomas (von Deimling et al., 1992) , the role of amplification of the c-erbB-2 gene has not been established in astrocytomas. A few studies using cell lines or a small number of tumours have not found abnormalities in c-erbB-2 oncogene or in its transcription (Saxena et al., 1992; Burgart et al., 1991; Natali et al., 1990 ), but two recent papers report common p185 overexpression in archival astrocytoma material (Bernstein et al., 1993; Schwechheimer et al., 1994) . The latter two studies suggested that p185 expression could be associated with tumorigenesis in astrocytomas, but the evaluation of the clinical value of p185 expression was based on a very limited subset of cases (Schwechheimer et al., 1994) .
In this study p185 protein expression was evaluated immunohistochemically in 94 archival paraffin-embedded astrocytomas using a monoclonal antibody specific to the external domain of the c-erbB-2 protein. antibodies were tested in paraffin-embedded breast cancer material, previously characterised for c-erbB-2 amplification and overexpression in frozen specimens (Press et al., 1994) .
The antibody used in the present study (TA250) was shown to have better sensitivity and specificity in the detection of amplification and overexpression than the antibody 3B5 -an observation that we also share (data not shown).
In line with the recent observations in ovarian and breast cancer (Morali et al., 1993; Press et al., 1994) , the p185 overexpression confined to cytoplasm of all three of our positive cases was not associated with c-erbB-2 amplification. The c-erbB-2 gene was not amplified in any of the ten (three immunopositive and seven indefinitely positive/negative) astrocytic tumours studied by dual colour FISH. The FISH technique used in the present study was recently introduced to improve the analysis of interphase nuclei of tumours that have been extensively fixed in formalin. Using this method, the amplification of the c-erbB-2 oncogene has been detected in formalin-fixed, paraffin-embedded breast cancer tissues with a high degree of concordance with the amplification in fresh tissues (Hyytinen et al., 1994) . The negative amplification result of the present study by FISH is consistent with the previous negative findings based on Southern hybridisation (n = 10) (Burgart et al., 1991) and DNA slot-blotting (n = 10) of astrocytomas (Schwechheimer et al., 1994) . It confirms that the TA250 antibody is highly efficient in the detection of c-erbB-2 amplification, as has been observed with breast cancer (Press et al., 1994) .
Together, these data show that the mechanism leading to p185-overexpression, although reported with variable frequency in different studies, is not the amplification of the cerbB-2 gene. An increase in gene transcription could be one possible explanation for the overexpression, but our findings of the aberrant localisation of the protein in cytoplasm, and not in cell membranes, suggest that there may be other reasons for the increased expression. One possibility is aberrant or incomplete glycosylation of the extracellular domain of the p185-protein, which could be related to the defective association of the p185-protein with the cell membrane (Morali et al., 1993) . Another possible explanation is the accumulation of the mutated protein in the cell due to the increased half-life of the protein, which happens after p53 mutations in many tumours, including astrocytomas. This is supported by a recent finding of point mutations in the transmembrane domain of the c-erbB-2 gene of four out of seven malignant astrocytic neoplasms (Kamitani et at., 1992).
In conclusion, our results suggest that p185 (c-erbB-2) overexpression is infrequent in astrocytomas, and that cerbB-2 oncogene amplification is not seen in the few cases in which there is cytoplasmic overexpression. The diagnostic and prognostic utility of p185 overexpression is limited. The reason for the phenomenon is unknown, and the results concerning the frequency of the phenomenon are confounding. The immunohistochemistry of p185 does not seem to have clinical value in the evaluation of astrocytic neoplasms.
